Antonio Marra, MD, Memorial Sloan Kettering Cancer Center, New York, NY, talks on an investigation into the genomic characterization of primary and metastatic HER2-low breast cancers. Using the FDA-cleared MSK-IMPACT assay from April 2014 to December 2021, using the clinical, pathological, and genomic data of BCs that were subjected to targeted sequencing were retrieved. Somatic mutations and DNA copy number alterations from MSK-IMPACT were analyzed. Hormone receptor (HR) expression was significantly higher in HER2-low than HER2-0 tumors in both primary and metastatic samples. A higher proportion of HER2-low tumors was found in metastatic than primary samples in this cohort. No difference in histology subtype, tumor grade, disease stage, mutational signatures, and tumor mutational burden was found overall and when cases were stratified by HR expression. In HR-positive BCs, HER2-0 BCs harbored higher frequency of TP53 and CDKN1A alterations than HER2-low breast cancer. These findings suggest HER2-low breast cancers do not represent a distinct biological subtype. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
